Results 181 to 190 of about 87,709 (275)
ERG assessment of altered retinal function in canine models of retinitis pigmentosa and monitoring of response to translatable gene augmentation therapy. [PDF]
Pasmanter N +2 more
europepmc +1 more source
We developed a RhPd‐H nanozyme that integrates enhanced POD‐mimetic catalytic activity with thermally triggered H2 release. H2 shields and reprograms mitochondria to continuously leak endogenous ·O2−. This dual‐path ROS spatially and temporally disrupts redox homeostasis, inducing persistent oxidative stress for tumor suppression and antitumor immunity,
Mingfan Shi +12 more
wiley +1 more source
Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in <b><i>RPE65</i></b>. [PDF]
Lorenz B.
europepmc +1 more source
Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. [PDF]
Barjaktarevic I, Miravitlles M.
europepmc +1 more source
Oral WT1‐targeted Bifidobacterium longum vaccine promotes WT1‐associated cellular immunity and enhances anti‐PD‐1/anti‐CTLA‐4 efficacy in pancreatic cancer. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immune checkpoint inhibitors (ICI) due to its profoundly immunosuppressive tumor microenvironment.
Taiki Yamazaki +7 more
wiley +1 more source
Fine-tuning FAM161A gene augmentation therapy to restore retinal function. [PDF]
Arsenijevic Y +12 more
europepmc +1 more source
ABSTRACT Platelet transfusions to treat bleeding complications use donor‐derived platelets stored at room‐temperature, that have a shelf‐life of only 5–7 days due to bacterial contamination risks. Cold‐stored and freeze‐dried platelets are being investigated for extending shelf‐life, but these still have the inherent challenge of donor‐dependency.
Ujjal Didar Singh Sekhon +20 more
wiley +1 more source
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral +7 more
wiley +1 more source
Assessing the efficacy of Alpha1-Proteinase inhibitor (human) augmentation therapy for Alpha1-Antitrypsin deficiency - Related emphysema: Challenges and opportunities. [PDF]
Pierce LR.
europepmc +1 more source
A temporally controlled drug release coating is developed for abutments using a superhydrophobic coating self‐assembled on mesoporous silica. This surface provides sequential functionality: initial contamination resistance through non‐wetting, followed by controlled drug release via wettability transition.
Zhongchao Wang +8 more
wiley +1 more source

